{
  "symbol": "JNJ",
  "year": 2024,
  "Period": "Y2024",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": 0.0324,
    "outlook_sentiment": 0.1683,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.6
  },
  "top_positive": [
    {
      "sent": "trends and the realization of benefits from the separation of the Company\u2019s Consumer Health Business \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected; \u2022 The Company\u2019s ability to divest the Company\u2019s remaining ownership interest in Kenvue Inc.",
      "score": 0.9559
    },
    {
      "sent": "(Kenvue) and realize the anticipated benefits from the separation; and \u2022 Kenvue's ability to succeed as a standalone publicly traded company.",
      "score": 0.7964
    },
    {
      "sent": "Financial statements and supplementary data Index to audited Consolidated Financial Statements Consolidated b alance s heets 44 Consolidated s tatements of e arnings 45 Consolidated s tatements of c omprehensive i ncome 46 Consolidated s tatements of e quity 47 Consolidated s tatements of c ash f lows 48 Notes to c onsolidated f inancial s tatements 50 Report of i ndependent r egistered p ublic a ccounting f irm (PCAOB ID 238 ) 106 Management\u2019s r eport on i nternal c ontrol o ver f inancial r eporting 109 2023 Annual Report 43 Johnson & Johnson and subsidiaries consolidated balance sheets At December\u00a031, 2023 and January\u00a01, 2023 (Dollars in Millions Except Share and Per Share Amounts) (Note\u00a01) 2023 2022 Assets Current assets Cash and cash equivalents (Notes\u00a01 and 2) $ 21,859 12,889 Marketable securities (Notes\u00a01 and 2) 1,068 9,392 Accounts receivable trade, less allowances $ 166 (2022, $ 169 ) 14,873 14,039 Inventories (Notes\u00a01 and 3) 11,181 10,268 Prepaid expenses and other receivables 4,514 2,876 Current assets of discontinued operations (Note 21) \u2014 5,830 Total current assets 53,495 55,294 Property, plant and equipment, net (Notes\u00a01 and 4) 19,898 17,982 Intangible assets, net (Notes\u00a01 and 5) 34,175 38,489 Goodwill (Notes\u00a01 and 5) 36,558 36,047 Deferred taxes on income (Note 8) 9,279 8,947 Other assets 14,153 9,212 Noncurrent assets of discontinued operations (Note 21) \u2014 21,407 Total assets $ 167,558 187,378 Liabilities and Shareholders\u2019 Equity Current liabilities Loans and notes payable (Note\u00a07) $ 3,451 12,756 Accounts payable 9,632 9,889 Accrued liabilities 10,212 10,719 Accrued rebates, returns and promotions 16,001 13,579 Accrued compensation and employee related obligations 3,993 3,049 Accrued taxes on income (Note 8) 2,993 2,220 Current liabilities of discontinued operations (Note 21) \u2014 3,590 Total current liabilities 46,282 55,802 Long-term debt (Note\u00a07) 25,881 26,886 Deferred taxes on income (Note 8) 3,193 3,991 Employee related obligations (Notes\u00a09 and 10) 7,149 6,542 Long-term taxes payable (Note 1) 2,881 4,306 Other liabilities 13,398 10,146 Noncurrent liabilities of discontinued operations (Note 21) \u2014 2,901 Total liabilities 98,784 110,574 Commitments and Contingencies (Note 19) Shareholders\u2019 equity Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000 shares) \u2014 \u2014 Common stock\u00a0\u2014 par value $ 1.00 per share (Note\u00a012) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120 Accumulated other comprehensive income (loss) (Note\u00a013) ( 12,527 ) ( 12,967 ) Retained earnings and Additional-paid-in-capital 153,843 128,345 Less: common stock held in treasury, at cost (Note\u00a012) ( 712,765,000 shares and 506,246,000 shares) 75,662 41,694 Total shareholders\u2019 equity 68,774 76,804 Total liabilities and shareholders\u2019 equity $ 167,558 187,378 See Notes to Consolidated Financial Statements 44 Johnson & Johnson and subsidiaries consolidated statements of\u00a0earnings (Dollars and Shares in Millions Except Per Share Amounts) (Note\u00a01) 2023 2022 2021 Sales to customers $ 85,159 79,990 78,740 Cost of products sold 26,553 24,596 23,402 Gross profit 58,606 55,394 55,338 Selling, marketing and administrative expenses 21,512 20,246 20,118 Research and development expense 15,085 14,135 14,277 In-process research and development impairments 313 783 900 Interest income ( 1,261 ) ( 490 ) ( 53 ) Interest expense, net of portion capitalized (Note\u00a04) 772 276 183 Other (income) expense, net 6,634 810 526 Restructuring (Note 20) 489 275 209 Earnings before provision for taxes on income 15,062 19,359 19,178 Provision for taxes on income (Note\u00a08) 1,736 2,989 1,377 Net earnings from continuing operations 13,326 16,370 17,801 Net earnings from discontinued operations, net of tax (Note 21) 21,827 1,571 3,077 Net earnings $ 35,153 17,941 20,878 Net earnings per share (Notes 1 and 15) Continuing operations - basic $ 5.26 6.23 6.76 Discontinued operations - basic $ 8.62 0.60 1.17 Total net earnings per share - basic $ 13.88 6.83 7.93 Continuing operations - diluted $ 5.20 6.14 6.66 Discontinued operations - diluted $ 8.52 0.59 1.15 Total net earnings per share - diluted $ 13.72 6.73 7.81 Average shares outstanding (Notes 1 and 15) Basic 2,533.5 2,625.2 2,632.1 Diluted 2,560.4 2,663.9 2,674.0 See Notes to Consolidated Financial Statements 2023 Annual Report 45 Johnson & Johnson and subsidiaries consolidated statements of comprehensive income (Dollars in Millions) (Note\u00a01) 2023 2022 2021 Net earnings $ 35,153 17,941 20,878 Other comprehensive income (loss), net of tax Foreign currency translation ( 3,221 ) ( 1,796 ) ( 1,079 ) Securities: Unrealized holding gain (loss) arising during period 26 ( 24 ) ( 4 ) Reclassifications to earnings \u2014 \u2014 \u2014 Net change 26 ( 24 ) ( 4 ) Employee benefit plans: Prior service credit (cost), net of amortization ( 149 ) ( 160 ) ( 169 ) Gain (loss), net of amortization ( 1,183 ) 1,854 4,318 Consumer settlement/ curtailment 23 \u2014 \u2014 Effect of exchange rates ( 90 ) 111 106 Net change ( 1,399 ) 1,805 4,255 Derivatives & hedges: Unrealized gain (loss) arising during period 422 454 ( 199 ) Reclassifications to earnings ( 569 ) ( 348 ) ( 789 ) Net change ( 147 ) 106 ( 988 ) Other comprehensive income (loss) ( 4,741 ) 91 2,184 Comprehensive income $ 30,412 18,032 23,062 The tax effects in other comprehensive income for the fiscal years 2023, 2022 and 2021 respectively: Foreign Currency Translation; $ 797 million, $ 460 million and $ 346 million; Employee Benefit Plans: $ 289 million, $ 461 million and $ 1,198 million, Derivatives & Hedges: $ 39 million, $ 30 million and $ 263 million.",
      "score": 0.9966
    },
    {
      "sent": "Financial statements and supplementary data Index to audited Consolidated Financial Statements Consolidated b alance s heets 44 Consolidated s tatements of e arnings 45 Consolidated s tatements of c omprehensive i ncome 46 Consolidated s tatements of e quity 47 Consolidated s tatements of c ash f lows 48 Notes to c onsolidated f inancial s tatements 50 Report of i ndependent r egistered p ublic a ccounting f irm (PCAOB ID 238 ) 106 Management\u2019s r eport on i nternal c ontrol o ver f inancial r eporting 109 2023 Annual Report 43 Johnson & Johnson and subsidiaries consolidated balance sheets At December\u00a031, 2023 and January\u00a01, 2023 (Dollars in Millions Except Share and Per Share Amounts) (Note\u00a01) 2023 2022 Assets Current assets Cash and cash equivalents (Notes\u00a01 and 2) $ 21,859 12,889 Marketable securities (Notes\u00a01 and 2) 1,068 9,392 Accounts receivable trade, less allowances $ 166 (2022, $ 169 ) 14,873 14,039 Inventories (Notes\u00a01 and 3) 11,181 10,268 Prepaid expenses and other receivables 4,514 2,876 Current assets of discontinued operations (Note 21) \u2014 5,830 Total current assets 53,495 55,294 Property, plant and equipment, net (Notes\u00a01 and 4) 19,898 17,982 Intangible assets, net (Notes\u00a01 and 5) 34,175 38,489 Goodwill (Notes\u00a01 and 5) 36,558 36,047 Deferred taxes on income (Note 8) 9,279 8,947 Other assets 14,153 9,212 Noncurrent assets of discontinued operations (Note 21) \u2014 21,407 Total assets $ 167,558 187,378 Liabilities and Shareholders\u2019 Equity Current liabilities Loans and notes payable (Note\u00a07) $ 3,451 12,756 Accounts payable 9,632 9,889 Accrued liabilities 10,212 10,719 Accrued rebates, returns and promotions 16,001 13,579 Accrued compensation and employee related obligations 3,993 3,049 Accrued taxes on income (Note 8) 2,993 2,220 Current liabilities of discontinued operations (Note 21) \u2014 3,590 Total current liabilities 46,282 55,802 Long-term debt (Note\u00a07) 25,881 26,886 Deferred taxes on income (Note 8) 3,193 3,991 Employee related obligations (Notes\u00a09 and 10) 7,149 6,542 Long-term taxes payable (Note 1) 2,881 4,306 Other liabilities 13,398 10,146 Noncurrent liabilities of discontinued operations (Note 21) \u2014 2,901 Total liabilities 98,784 110,574 Commitments and Contingencies (Note 19) Shareholders\u2019 equity Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000 shares) \u2014 \u2014 Common stock\u00a0\u2014 par value $ 1.00 per share (Note\u00a012) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120 Accumulated other comprehensive income (loss) (Note\u00a013) ( 12,527 ) ( 12,967 ) Retained earnings and Additional-paid-in-capital 153,843 128,345 Less: common stock held in treasury, at cost (Note\u00a012) ( 712,765,000 shares and 506,246,000 shares) 75,662 41,694 Total shareholders\u2019 equity 68,774 76,804 Total liabilities and shareholders\u2019 equity $ 167,558 187,378 See Notes to Consolidated Financial Statements 44 Johnson & Johnson and subsidiaries consolidated statements of\u00a0earnings (Dollars and Shares in Millions Except Per Share Amounts) (Note\u00a01) 2023 2022 2021 Sales to customers $ 85,159 79,990 78,740 Cost of products sold 26,553 24,596 23,402 Gross profit 58,606 55,394 55,338 Selling, marketing and administrative expenses 21,512 20,246 20,118 Research and development expense 15,085 14,135 14,277 In-process research and development impairments 313 783 900 Interest income ( 1,261 ) ( 490 ) ( 53 ) Interest expense, net of portion capitalized (Note\u00a04) 772 276 183 Other (income) expense, net 6,634 810 526 Restructuring (Note 20) 489 275 209 Earnings before provision for taxes on income 15,062 19,359 19,178 Provision for taxes on income (Note\u00a08) 1,736 2,989 1,377 Net earnings from continuing operations 13,326 16,370 17,801 Net earnings from discontinued operations, net of tax (Note 21) 21,827 1,571 3,077 Net earnings $ 35,153 17,941 20,878 Net earnings per share (Notes 1 and 15) Continuing operations - basic $ 5.26 6.23 6.76 Discontinued operations - basic $ 8.62 0.60 1.17 Total net earnings per share - basic $ 13.88 6.83 7.93 Continuing operations - diluted $ 5.20 6.14 6.66 Discontinued operations - diluted $ 8.52 0.59 1.15 Total net earnings per share - diluted $ 13.72 6.73 7.81 Average shares outstanding (Notes 1 and 15) Basic 2,533.5 2,625.2 2,632.1 Diluted 2,560.4 2,663.9 2,674.0 See Notes to Consolidated Financial Statements 2023 Annual Report 45 Johnson & Johnson and subsidiaries consolidated statements of comprehensive income (Dollars in Millions) (Note\u00a01) 2023 2022 2021 Net earnings $ 35,153 17,941 20,878 Other comprehensive income (loss), net of tax Foreign currency translation ( 3,221 ) ( 1,796 ) ( 1,079 ) Securities: Unrealized holding gain (loss) arising during period 26 ( 24 ) ( 4 ) Reclassifications to earnings \u2014 \u2014 \u2014 Net change 26 ( 24 ) ( 4 ) Employee benefit plans: Prior service credit (cost), net of amortization ( 149 ) ( 160 ) ( 169 ) Gain (loss), net of amortization ( 1,183 ) 1,854 4,318 Consumer settlement/ curtailment 23 \u2014 \u2014 Effect of exchange rates ( 90 ) 111 106 Net change ( 1,399 ) 1,805 4,255 Derivatives & hedges: Unrealized gain (loss) arising during period 422 454 ( 199 ) Reclassifications to earnings ( 569 ) ( 348 ) ( 789 ) Net change ( 147 ) 106 ( 988 ) Other comprehensive income (loss) ( 4,741 ) 91 2,184 Comprehensive income $ 30,412 18,032 23,062 The tax effects in other comprehensive income for the fiscal years 2023, 2022 and 2021 respectively: Foreign Currency Translation; $ 797 million, $ 460 million and $ 346 million; Employee Benefit Plans: $ 289 million, $ 461 million and $ 1,198 million, Derivatives & Hedges: $ 39 million, $ 30 million and $ 263 million.",
      "score": 0.9966
    },
    {
      "sent": "The Company\u2019s human capital management strategy is built on three fundamental focus areas: \u2022 Attracting and recruiting the best talent \u2022 Developing and retaining talent \u2022 Empowering and inspiring talent Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on diversity, equity and inclusion (DEI), innovation, health, well-being and safety, where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals.",
      "score": 0.9831
    }
  ],
  "top_negative": [
    {
      "sent": "Risks related to economic conditions, financial markets and operating internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal\u00a0systems; \u2022 The impact of global public health crises and pandemics; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; \u2022 The impact of global or economic changes or events, including global tensions and war; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.",
      "score": -0.9531
    },
    {
      "sent": "Risks related to supply chain and operations \u2022 Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action; \u2022 Interruptions and breaches of the Company\u2019s information technology systems or those of the Company\u2019s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; \u2022 Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company\u2019s products; and \u2022 The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.",
      "score": -0.765
    },
    {
      "sent": "Key products in the Innovative Medicine segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; EDURANT (rilpivirine), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV) in combination with other antiretroviral products and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months; SPRAVATO (Esketamine), a nasal spray, used along with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions; CARVYKTI (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR)-T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma; ZYTIGA (abiraterone 2023 Annual Report 1 acetate), a treatment for patients with prostate cancer; ERLEADA (apalutamide), a\u00a0next- generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a\u00a0treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; OPSUMIT (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH.",
      "score": -0.9612
    },
    {
      "sent": "Key products in the Innovative Medicine segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; EDURANT (rilpivirine), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV) in combination with other antiretroviral products and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months; SPRAVATO (Esketamine), a nasal spray, used along with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions; CARVYKTI (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR)-T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma; ZYTIGA (abiraterone 2023 Annual Report 1 acetate), a treatment for patients with prostate cancer; ERLEADA (apalutamide), a\u00a0next- generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a\u00a0treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; OPSUMIT (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH.",
      "score": -0.9612
    },
    {
      "sent": "Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.",
      "score": -0.8658
    }
  ],
  "forward_snippets": [
    "In any event, we anticipate that the selected products will be subjected to a government-established price for the Medicare population.",
    "Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels, which may result in additional regulations or other mechanisms to increase pricing transparency and controls.",
    "Employees worldwide must adhere to the Company\u2019s Code of Business Conduct which sets basic requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates.",
    "The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies.",
    "Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels, which may result in additional regulations or other mechanisms to increase pricing transparency and controls."
  ],
  "curated_text": "Symbol: JNJ. Year: 2024. Period: Y2024. ReportType: K10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: trends and the realization of benefits from the separation of the Company\u2019s Consumer Health Business \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected; \u2022 The Company\u2019s ability to divest the Company\u2019s remaining ownership interest in Kenvue Inc. (Kenvue) and realize the anticipated benefits from the separation; and \u2022 Kenvue's ability to succeed as a standalone publicly traded company. Financial statements and supplementary data Index to audited Consolidated Financial Statements Consolidated b alance s heets 44 Consolidated s tatements of e arnings 45 Consolidated s tatements of c omprehensive i ncome 46 Consolidated s tatements of e quity 47 Consolidated s tatements of c ash f lows 48 Notes to c onsolidated f inancial s tatements 50 Report of i ndependent r egistered p ublic a ccounting f irm (PCAOB ID 238 ) 106 Management\u2019s r eport on i nternal c ontrol o ver f inancial r eporting 109 2023 Annual Report 43 Johnson & Johnson and subsidiaries consolidated balance sheets At December\u00a031, 2023 and January\u00a01, 2023 (Dollars in Millions Except Share and Per Share Amounts) (Note\u00a01) 2023 2022 Assets Current assets Cash and cash equivalents (Notes\u00a01 and 2) $ 21,859 12,889 Marketable securities (Notes\u00a01 and 2) 1,068 9,392 Accounts receivable trade, less allowances $ 166 (2022, $ 169 ) 14,873 14,039 Inventories (Notes\u00a01 and 3) 11,181 10,268 Prepaid expenses and other receivables 4,514 2,876 Current assets of discontinued operations (Note 21) \u2014 5,830 Total current assets 53,495 55,294 Property, plant and equipment, net (Notes\u00a01 and 4) 19,898 17,982 Intangible assets, net (Notes\u00a01 and 5) 34,175 38,489 Goodwill (Notes\u00a01 and 5) 36,558 36,047 Deferred taxes on income (Note 8) 9,279 8,947 Other assets 14,153 9,212 Noncurrent assets of discontinued operations (Note 21) \u2014 21,407 Total assets $ 167,558 187,378 Liabilities and Shareholders\u2019 Equity Current liabilities Loans and notes payable (Note\u00a07) $ 3,451 12,756 Accounts payable 9,632 9,889 Accrued liabilities 10,212 10,719 Accrued rebates, returns and promotions 16,001 13,579 Accrued compensation and employee related obligations 3,993 3,049 Accrued taxes on income (Note 8) 2,993 2,220 Current liabilities of discontinued operations (Note 21) \u2014 3,590 Total current liabilities 46,282 55,802 Long-term debt (Note\u00a07) 25,881 26,886 Deferred taxes on income (Note 8) 3,193 3,991 Employee related obligations (Notes\u00a09 and 10) 7,149 6,542 Long-term taxes payable (Note 1) 2,881 4,306 Other liabilities 13,398 10,146 Noncurrent liabilities of discontinued operations (Note 21) \u2014 2,901 Total liabilities 98,784 110,574 Commitments and Contingencies (Note 19) Shareholders\u2019 equity Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000 shares) \u2014 \u2014 Common stock\u00a0\u2014 par value $ 1.00 per share (Note\u00a012) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120 Accumulated other comprehensive income (loss) (Note\u00a013) ( 12,527 ) ( 12,967 ) Retained earnings and Additional-paid-in-capital 153,843 128,345 Less: common stock held in treasury, at cost (Note\u00a012) ( 712,765,000 shares and 506,246,000 shares) 75,662 41,694 Total shareholders\u2019 equity 68,774 76,804 Total liabilities and shareholders\u2019 equity $ 167,558 187,378 See Notes to Consolidated Financial Statements 44 Johnson & Johnson and subsidiaries consolidated statements of\u00a0earnings (Dollars and Shares in Millions Except Per Share Amounts) (Note\u00a01) 2023 2022 2021 Sales to customers $ 85,159 79,990 78,740 Cost of products sold 26,553 24,596 23,402 Gross profit 58,606 55,394 55,338 Selling, marketing and administrative expenses 21,512 20,246 20,118 Research and development expense 15,085 14,135 14,277 In-process research and development impairments 313 783 900 Interest income ( 1,261 ) ( 490 ) ( 53 ) Interest expense, net of portion capitalized (Note\u00a04) 772 276 183 Other (income) expense, net 6,634 810 526 Restructuring (Note 20) 489 275 209 Earnings before provision for taxes on income 15,062 19,359 19,178 Provision for taxes on income (Note\u00a08) 1,736 2,989 1,377 Net earnings from continuing operations 13,326 16,370 17,801 Net earnings from discontinued operations, net of tax (Note 21) 21,827 1,571 3,077 Net earnings $ 35,153 17,941 20,878 Net earnings per share (Notes 1 and 15) Continuing operations - basic $ 5.26 6.23 6.76 Discontinued operations - basic $ 8.62 0.60 1.17 Total net earnings per share - basic $ 13.88 6.83 7.93 Continuing operations - diluted $ 5.20 6.14 6.66 Discontinued operations - diluted $ 8.52 0.59 1.15 Total net earnings per share - diluted $ 13.72 6.73 7.81 Average shares outstanding (Notes 1 and 15) Basic 2,533.5 2,625.2 2,632.1 Diluted 2,560.4 2,663.9 2,674.0 See Notes to Consolidated Financial Statements 2023 Annual Report 45 Johnson & Johnson and subsidiaries consolidated statements of comprehensive income (Dollars in Millions) (Note\u00a01) 2023 2022 2021 Net earnings $ 35,153 17,941 20,878 Other comprehensive income (loss), net of tax Foreign currency translation ( 3,221 ) ( 1,796 ) ( 1,079 ) Securities: Unrealized holding gain (loss) arising during period 26 ( 24 ) ( 4 ) Reclassifications to earnings \u2014 \u2014 \u2014 Net change 26 ( 24 ) ( 4 ) Employee benefit plans: Prior service credit (cost), net of amortization ( 149 ) ( 160 ) ( 169 ) Gain (loss), net of amortization ( 1,183 ) 1,854 4,318 Consumer settlement/ curtailment 23 \u2014 \u2014 Effect of exchange rates ( 90 ) 111 106 Net change ( 1,399 ) 1,805 4,255 Derivatives & hedges: Unrealized gain (loss) arising during period 422 454 ( 199 ) Reclassifications to earnings ( 569 ) ( 348 ) ( 789 ) Net change ( 147 ) 106 ( 988 ) Other comprehensive income (loss) ( 4,741 ) 91 2,184 Comprehensive income $ 30,412 18,032 23,062 The tax effects in other comprehensive income for the fiscal years 2023, 2022 and 2021 respectively: Foreign Currency Translation; $ 797 million, $ 460 million and $ 346 million; Employee Benefit Plans: $ 289 million, $ 461 million and $ 1,198 million, Derivatives & Hedges: $ 39 million, $ 30 million and $ 263 million. Financial statements and supplementary data Index to audited Consolidated Financial Statements Consolidated b alance s heets 44 Consolidated s tatements of e arnings 45 Consolidated s tatements of c omprehensive i ncome 46 Consolidated s tatements of e quity 47 Consolidated s tatements of c ash f lows 48 Notes to c onsolidated f inancial s tatements 50 Report of i ndependent r egistered p ublic a ccounting f irm (PCAOB ID 238 ) 106 Management\u2019s r eport on i nternal c ontrol o ver f inancial r eporting 109 2023 Annual Report 43 Johnson & Johnson and subsidiaries consolidated balance sheets At December\u00a031, 2023 and January\u00a01, 2023 (Dollars in Millions Except Share and Per Share Amounts) (Note\u00a01) 2023 2022 Assets Current assets Cash and cash equivalents (Notes\u00a01 and 2) $ 21,859 12,889 Marketable securities (Notes\u00a01 and 2) 1,068 9,392 Accounts receivable trade, less allowances $ 166 (2022, $ 169 ) 14,873 14,039 Inventories (Notes\u00a01 and 3) 11,181 10,268 Prepaid expenses and other receivables 4,514 2,876 Current assets of discontinued operations (Note 21) \u2014 5,830 Total current assets 53,495 55,294 Property, plant and equipment, net (Notes\u00a01 and 4) 19,898 17,982 Intangible assets, net (Notes\u00a01 and 5) 34,175 38,489 Goodwill (Notes\u00a01 and 5) 36,558 36,047 Deferred taxes on income (Note 8) 9,279 8,947 Other assets 14,153 9,212 Noncurrent assets of discontinued operations (Note 21) \u2014 21,407 Total assets $ 167,558 187,378 Liabilities and Shareholders\u2019 Equity Current liabilities Loans and notes payable (Note\u00a07) $ 3,451 12,756 Accounts payable 9,632 9,889 Accrued liabilities 10,212 10,719 Accrued rebates, returns and promotions 16,001 13,579 Accrued compensation and employee related obligations 3,993 3,049 Accrued taxes on income (Note 8) 2,993 2,220 Current liabilities of discontinued operations (Note 21) \u2014 3,590 Total current liabilities 46,282 55,802 Long-term debt (Note\u00a07) 25,881 26,886 Deferred taxes on income (Note 8) 3,193 3,991 Employee related obligations (Notes\u00a09 and 10) 7,149 6,542 Long-term taxes payable (Note 1) 2,881 4,306 Other liabilities 13,398 10,146 Noncurrent liabilities of discontinued operations (Note 21) \u2014 2,901 Total liabilities 98,784 110,574 Commitments and Contingencies (Note 19) Shareholders\u2019 equity Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000 shares) \u2014 \u2014 Common stock\u00a0\u2014 par value $ 1.00 per share (Note\u00a012) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120 Accumulated other comprehensive income (loss) (Note\u00a013) ( 12,527 ) ( 12,967 ) Retained earnings and Additional-paid-in-capital 153,843 128,345 Less: common stock held in treasury, at cost (Note\u00a012) ( 712,765,000 shares and 506,246,000 shares) 75,662 41,694 Total shareholders\u2019 equity 68,774 76,804 Total liabilities and shareholders\u2019 equity $ 167,558 187,378 See Notes to Consolidated Financial Statements 44 Johnson & Johnson and subsidiaries consolidated statements of\u00a0earnings (Dollars and Shares in Millions Except Per Share Amounts) (Note\u00a01) 2023 2022 2021 Sales to customers $ 85,159 79,990 78,740 Cost of products sold 26,553 24,596 23,402 Gross profit 58,606 55,394 55,338 Selling, marketing and administrative expenses 21,512 20,246 20,118 Research and development expense 15,085 14,135 14,277 In-process research and development impairments 313 783 900 Interest income ( 1,261 ) ( 490 ) ( 53 ) Interest expense, net of portion capitalized (Note\u00a04) 772 276 183 Other (income) expense, net 6,634 810 526 Restructuring (Note 20) 489 275 209 Earnings before provision for taxes on income 15,062 19,359 19,178 Provision for taxes on income (Note\u00a08) 1,736 2,989 1,377 Net earnings from continuing operations 13,326 16,370 17,801 Net earnings from discontinued operations, net of tax (Note 21) 21,827 1,571 3,077 Net earnings $ 35,153 17,941 20,878 Net earnings per share (Notes 1 and 15) Continuing operations - basic $ 5.26 6.23 6.76 Discontinued operations - basic $ 8.62 0.60 1.17 Total net earnings per share - basic $ 13.88 6.83 7.93 Continuing operations - diluted $ 5.20 6.14 6.66 Discontinued operations - diluted $ 8.52 0.59 1.15 Total net earnings per share - diluted $ 13.72 6.73 7.81 Average shares outstanding (Notes 1 and 15) Basic 2,533.5 2,625.2 2,632.1 Diluted 2,560.4 2,663.9 2,674.0 See Notes to Consolidated Financial Statements 2023 Annual Report 45 Johnson & Johnson and subsidiaries consolidated statements of comprehensive income (Dollars in Millions) (Note\u00a01) 2023 2022 2021 Net earnings $ 35,153 17,941 20,878 Other comprehensive income (loss), net of tax Foreign currency translation ( 3,221 ) ( 1,796 ) ( 1,079 ) Securities: Unrealized holding gain (loss) arising during period 26 ( 24 ) ( 4 ) Reclassifications to earnings \u2014 \u2014 \u2014 Net change 26 ( 24 ) ( 4 ) Employee benefit plans: Prior service credit (cost), net of amortization ( 149 ) ( 160 ) ( 169 ) Gain (loss), net of amortization ( 1,183 ) 1,854 4,318 Consumer settlement/ curtailment 23 \u2014 \u2014 Effect of exchange rates ( 90 ) 111 106 Net change ( 1,399 ) 1,805 4,255 Derivatives & hedges: Unrealized gain (loss) arising during period 422 454 ( 199 ) Reclassifications to earnings ( 569 ) ( 348 ) ( 789 ) Net change ( 147 ) 106 ( 988 ) Other comprehensive income (loss) ( 4,741 ) 91 2,184 Comprehensive income $ 30,412 18,032 23,062 The tax effects in other comprehensive income for the fiscal years 2023, 2022 and 2021 respectively: Foreign Currency Translation; $ 797 million, $ 460 million and $ 346 million; Employee Benefit Plans: $ 289 million, $ 461 million and $ 1,198 million, Derivatives & Hedges: $ 39 million, $ 30 million and $ 263 million. The Company\u2019s human capital management strategy is built on three fundamental focus areas: \u2022 Attracting and recruiting the best talent \u2022 Developing and retaining talent \u2022 Empowering and inspiring talent Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on diversity, equity and inclusion (DEI), innovation, health, well-being and safety, where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals. Top negative sentences: Risks related to economic conditions, financial markets and operating internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal\u00a0systems; \u2022 The impact of global public health crises and pandemics; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; \u2022 The impact of global or economic changes or events, including global tensions and war; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets. Risks related to supply chain and operations \u2022 Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action; \u2022 Interruptions and breaches of the Company\u2019s information technology systems or those of the Company\u2019s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; \u2022 Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company\u2019s products; and \u2022 The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. Key products in the Innovative Medicine segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; EDURANT (rilpivirine), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV) in combination with other antiretroviral products and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months; SPRAVATO (Esketamine), a nasal spray, used along with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions; CARVYKTI (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR)-T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma; ZYTIGA (abiraterone 2023 Annual Report 1 acetate), a treatment for patients with prostate cancer; ERLEADA (apalutamide), a\u00a0next- generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a\u00a0treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; OPSUMIT (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Key products in the Innovative Medicine segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; EDURANT (rilpivirine), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV) in combination with other antiretroviral products and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months; SPRAVATO (Esketamine), a nasal spray, used along with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions; CARVYKTI (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR)-T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma; ZYTIGA (abiraterone 2023 Annual Report 1 acetate), a treatment for patients with prostate cancer; ERLEADA (apalutamide), a\u00a0next- generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a\u00a0treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; OPSUMIT (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Forward-looking snippets: In any event, we anticipate that the selected products will be subjected to a government-established price for the Medicare population. Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels, which may result in additional regulations or other mechanisms to increase pricing transparency and controls. Employees worldwide must adhere to the Company\u2019s Code of Business Conduct which sets basic requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates. The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies. Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels, which may result in additional regulations or other mechanisms to increase pricing transparency and controls."
}